Although the cardiovascular safety of DPP-4 inhibitors has been proven in T2DM, the net effect of these drugs on leptin concentrations in obesity-related disease remains unclear [24]. This evidence concerns the gene LEP and obesity due to melanocortin 4 receptor deficiency.